Have a feature idea you'd love to see implemented?
Let us know!
Back to SPRY overview
SPRY ARS Pharmaceuticals PE ratio, current and historical analysis
The current P/E ratio of SPRY cannot be calculated, as the latest EPS of -$0.51 is negative. The most recent PE ratio recorded for ARS Pharmaceuticals was 9.96 in September 2022.
SPRY PE ratio history
How has SPRY's PE ratio performed in the past
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
ARS Pharmaceuticals PE ratio by year
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | N/A | N/A |
| 2021 | N/A | N/A |
| 2020 | N/A | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
SPRY average PE ratio chart
What is the average PE ratio of SPRY for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
SPRY PE vs peers
What is SPRY's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| ORMP Oramed Pharmaceuticals Inc | 21 | $93.12M |
| OLMA Olema Pharmaceuticals Inc | N/A | $450.93M |
| OMER Omeros Corp | N/A | $447.95M |
| OMGA Omega Therapeutics Inc | N/A | $42.96M |
| ONCT Oncternal Therapeutics Inc | N/A | $3.43M |
| ONVO Organovo Holdings Inc | N/A | $5.38M |
| ORIC Oric Pharmaceuticals Inc | N/A | $643.57M |
| SPRY ARS Pharmaceuticals Inc | N/A | $1.3B |
Frequently asked questions
What is ARS Pharmaceuticals's PE ratio?
The current price to earnings ratio of SPRY cannot be determined, as its EPS of -$0.51 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.